Skip to Content

Project 1: Early Detection of Epithelial Ovarian Cancer

Publications

Note: Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Zhang Z, Barnhill SD, Xu FJ, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC Jr. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999; 73:56-61. PMID: 10094881.
    Abstract
  2. Woolas RP, Oram DH, Davies AP, Bast RC Jr, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging examination. Int J Gyn Cancer 1999; 9:497-501. PMID: 11240818.
    Abstract
  3. Hogdall EVS, Hogdall CK, Kjaer SK, Iles R, Xu FJ, Yu, Y, Bast RC Jr, Blaakaer J, Jacobs I. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clinical Chemistry 1999; 45:692-694. PMID: 10222361.
    Abstract
  4. Hodgall EVS, Hogdall C, Hagen B, Tingulstad S, Nustad K, Xu F, Bast RC Jr, Jacobs I. The predictive values of the serum tumor markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000; 89:519-23. PMID: 11102897.
    Abstract
  5. Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V, Sjövall K. Long-term follow-up of the Stockholm Screening Study on Ovarian Cancer. Gynecol Oncol 2000; 79:466-470. PMID: 11104621.
    Abstract
  6. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, James D, Kalli K, Keeney G, Roche P, Cliby W, Schmandt R, Mills GB, Bast RC Jr, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early versus late stage ovarian tumors. Cancer Res 2001; 61:5895-5904. PMID: 11479231.
    Abstract
  7. Van Haaften-Day C, Xu F, Yu Y, Bast RC Jr, Hacker N. OVX1, CA 125 and M-CSF as tumor markers for surface epithelial-stromal tumors of the ovary - a critical appraisal. Cancer 2001; 92:2837-44. PMID: 11753957.
    Abstract
  8. Mills GB, Bast RC Jr, Srivastava S. Editorial: Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001; 93(19):1437-9. PMID: 11584052.
    Abstract
  9. Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills GB. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002; 107:61-97. PMID: 11775462.
    [no link available]
  10. Skates SJ. Screening for ovarian cancer-risk, education, worry: path to appropriate use? Gynecol Oncol. 2002 Apr;85(1):1-2. PMID: 11925112.
    Abstract
  11. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002 Apr 3;287(13):1671-9. PMID: 11926891.
    Abstract
  12. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003; 21:200s-5s. PMID: 12743135.
    Abstract
  13. Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol, 2003; 21(10 Suppl):129s-32s. PMID: 12743127.
    Full Text
  14. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003; 90(1):44-50. PMID: 12743127.
    Full Text
  15. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinogenesis 2003; 36:53-9. PMID: 12557260.
    Abstract
  16. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21(10 Suppl):206s-10s. PMID: 12743136.
    Abstract
  17. Skates SJ, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2003; Sep-Oct;13(5):693-6. PMID: 14675358.
    Abstract
  18. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai A, Rosenzweig JM, Cameron B, Meng X-Y, Berchuck A, van Haaften-Day C, Hacker NF, de Bruijn HWA, van der Zee, A, Jacobs IJ, Fung ET, Chan D. A panel of serum biomarkers identified through proteomic profiling for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882-90. PMID: 15313933.
    Abstract
  19. Skates SJ, Horick N, Yu Y, Xu F-J, Berchuck A, Havrilesky L, de Bruihn HW, van der Zee AGJ, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr. Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA 125, CA 15.3, CA 72.4 and M-CSF using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22:4059-66. PMID: 15381683.
    Abstract
  20. Bast RC Jr. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Amer Clin Climatological Assoc 2004; 115: 233-248. PMCID: PMC2263776.
    [no link available]
  21. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004; 279):9653-61. PMID: 14670967.
    Abstract
  22. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth L, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10:3291-3300. PMID: 15161682.
    Abstract
  23. Liu J, Yang G, Thompson-Lanza JA, Glasman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC Jr. A genetically defined mouse model for human ovarian cancer. Cancer Res 2004; 64:1655-63. PMID: 14996724.
    Abstract
  24. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 1;11(17):6116-26. PMID: 16144910.
    Abstract
  25. Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Cancer Res. 2005 Sep 1;11(17):6103-8. PMID: 16144908.
    Abstract
  26. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov;99(2):267-77. Epub 2005 Aug 2. PMID: 16061277.
    Abstract
  27. Young T, Mei F, Liu J, Bast RC Jr, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene. 2005 Sep 8;24(40):6174-84. PMCID: PMC1201440.
    Abstract
  28. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15;65(22):10602-12. PMID: 16288054.
    Abstract
  29. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005 Nov 1;23(31):7919-26. PMID: 16258091.
    Abstract
  30. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006 Jan 15;66(2):1181-90. PMCID: PMC2546578.
    Abstract
  31. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review. PMID: 16343244.
    Abstract
  32. Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol. 2006 Feb;100(2):247-53. PMID: 16229881.
    Full Text
  33. Yu W, Wu B, Liu J, Li X, Stone K, Williams KR, Zhao H. MALDI-MS data analysis for disease biomarker discovery. Methods Mol Biol. 2006;328:199-216. PMID: 16785651.
    Abstract
  34. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007;174:91-100. PMID: 17302189.
    [no link available]
  35. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol. 2007 Sep;106(3):490-7. Epub 2007 May 25. PMID: 17532030.
    Abstract
  36. Farley J, Bast RC Jr, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S3-5. Epub 2006 Oct 5. No abstract available. PMID: 17027069.
    Full Text
  37. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008 Mar;108(3):652-7. Epub 2007 Dec 21. PMID: 18096210.
    Full Text
  38. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers. 2007;23(5-6):397-410. Review. PMID: 18057523.
    Abstract
  39. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008 Feb;108(2):402-8. Epub 2007 Dec 3. PMID: 18061248.
    Abstract
  40. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007 Dec;107(3):526-31. Epub 2007 Oct 24. PMCID: PMC2171045.
    Abstract
  41. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007 Nov;107(2):173-6. PMID: 17950384.
    Abstract
  42. Moore RG, McMeekin DS, Brown AK, Disilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009 Jan;112(1):40-6. Epub 2008 Oct 12. PMID: 18851871.
    Abstract
  43. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 Jun;9(6):415-28. PMID: 19461667.
    Full Text (pdf)
  44. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. Epub 2009 Mar 11. PMID: 19282241.
    Full Text
  45. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 2009;112(1):60-7. PMID: 19007973.
    Full Text

© 2014 The University of Texas MD Anderson Cancer Center